Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CHRO

Channel Therapeutics Corporation

Dec 10 • 04:00PM ET

0.6200

Dollar change -0.0865
Percentage change -12.24	%

Healthcare • Biotechnology • USA • AMEX

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	73.29%	Shs Outstand	5.82M	Perf Week	-4.76%
Market Cap	3.74M	Forward P/E	-	EPS next Y	-	Insider Trans	0.63%	Shs Float	1.61M	Perf Month	-5.70%
Income	-10.07M	PEG	-	EPS next Q	-	Inst Own	1.98%	Short Float	1.89%	Perf Quarter	-35.44%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-76.81%	Short Ratio	0.19	Perf Half Y	-53.03%
Book/sh	-0.25	P/B	-	EPS next Y	-	ROA	-931.05%	Short Interest	0.03M	Perf Year	-
Cash/sh	0.21	P/C	2.99	EPS next 5Y	-	ROE	-	52W Range	0.45 - 6.00	Perf YTD	-87.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-89.67%	Beta	-
Dividend TTM	-	Quick Ratio	0.39	Sales past 5Y	-33.33%	Gross Margin	-	52W Low	37.78%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	0.39	EPS Y/Y TTM	-144.62%	Oper. Margin	-	RSI (14)	46.99	Volatility	20.22% 16.60%
Employees	8	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-18.70%	Payout	-	Rel Volume	0.99	Prev Close	0.71
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 28	Avg Volume	159.31K	Price	0.62
SMA20	-3.44%	SMA50	-5.32%	SMA200	-54.90%	Trades		Volume	156,121	Change	-12.24%

Nov-21-24 09:49AM	Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates (GlobeNewswire)
Oct-29-24 08:30AM	Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain (GlobeNewswire) +6.80%
Oct-28-24 08:00AM	Chromocell to Present at Upcoming Fall Investor Conferences (GlobeNewswire) -10.42%
Oct-24-24 08:45AM	Chromocell Announces Amendment to Stock Repurchase Plan (GlobeNewswire) +13.10%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
12:07PM	Loading…
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -8.16%
08:35AM	Chromocell to Participate in Life Sciences Investor Forum September 19th (GlobeNewswire)
Sep-03-24 09:00AM	Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.60%
Aug-07-24 08:45AM	Chromocell Announces Stock Repurchase Plan (GlobeNewswire)
Jul-15-24 09:00AM	Chromocell to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
May-13-24 09:00AM	Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024 (GlobeNewswire) +38.25%
Apr-09-24 08:30AM	Chromocell Issues Letter to Stockholders from Chief Executive Officer (GlobeNewswire) -8.37%
Mar-21-24 08:30AM	Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler (GlobeNewswire)
Mar-18-24 10:00AM	Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 (GlobeNewswire) -5.44%
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
09:00AM	Loading…
Mar-11-24 09:00AM	Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 (GlobeNewswire) -6.31%
Feb-27-24 08:00AM	Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions (GlobeNewswire)
Feb-21-24 04:47PM	Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million (GlobeNewswire)
Feb-16-24 08:00AM	Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering (GlobeNewswire)

Channel Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company was founded on November 18, 2024 and is headquartered in Freehold, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malamut Richard	Director	Sep 12 '24	Buy	0.94	10,400	9,825	91,565	Sep 16 04:56 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 13 '24	Buy	0.97	3,500	3,395	547,710	Sep 16 04:55 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 12 '24	Buy	0.97	1,700	1,649	544,210	Sep 16 04:55 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 10 '24	Buy	0.89	6,500	5,785	537,010	Sep 12 05:35 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 11 '24	Buy	0.94	5,500	5,170	542,510	Sep 12 05:35 PM
Davis Todd C	Director	Feb 21 '24	Option Exercise	4.80	29,167	140,002	29,167	Feb 23 05:15 PM
Friedberg Ezra M	Director	Feb 21 '24	Option Exercise	4.80	20,641	99,077	520,719	Feb 23 05:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRO

Channel Therapeutics Corporation

Upgrade your FINVIZ experience